Abstract 2978
Background
Cancer and diabetes are prevalent diseases worldwide. The purpose of this study was to assess quality of life and the factors influence it in the individuals with coexistence diabetes type 2 and cancer.
Methods
A cross-sectional study was conducted in a large hospital in a major Greek city. Convenience sample of 101 patients with cancer and diabetes type 2 undergoing chemotherapy constituted the study group. Quality of life was measured by the Audit of Diabetes Depedent-QoL-Questionnaire (ADDQoL-19). Information on social-demographic, treatment of tumors and diabetes, and other clinical characteristics were collected by other questionnaire. Descriptive statistics were used for demographic characteristics. For data that were not normally distributed, nonparametric tests (Mann-Whitney U test, Kruskal-Wallis test) were applied.
Results
The majority of patients had cancer stage II (n = 52, 51,5%) and diabetes 2 for almost seven years. Individuals with coexistence of diabetes 2 and cancer reported that disease affected the overall quality of life (1.84±1.18). Also, there is a negative score in other subscale as freedom to eat (-1.43 ±0.80) and financial situation (-1.25±0,84). It was found that cancer’s stage influences the general quality of life domain (p = 0.023). Also, there were statistical significant differences between type of regimen for diabetes and several domains of quality of life. More particular, working life (p = 0.004), family life (p = 0.003), friendship and social life (p = 0.005), physical health (p = 0.003), leisure activities (p = 0.004) and financial situation (p = 0.004) are some of these domains that they are further influenced. Additionally the family status influences self-confidence (p = 0.001) and motivation (p = 0.007).
Conclusions
Taking all the above under consideration, we conclude that social-demographic and clinical characteristics were associated with quality of life in patients with cancer and diabetes 2.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
5105 - Fresh blood Immune cell monitoring in patients treated with nivolumab in the GETUG-AFU26 NIVOREN study: association with toxicity and treatment outcome
Presenter: Aude DESNOYER
Session: Poster Display session 3
Resources:
Abstract
1877 - Advanced clear-cell renal cell carcinoma (accRCC): association of microRNAs (miRNAs) with molecular subtypes, mRNA targets and outcome.
Presenter: Annelies Verbiest
Session: Poster Display session 3
Resources:
Abstract
5543 - Prior tyrosine kinase inhibitors (TKI) and antibiotics (ATB) use are associated with distinct gut microbiota ‘guilds’ in renal cell carcinoma (RCC) patients
Presenter: Valerio Iebba
Session: Poster Display session 3
Resources:
Abstract
2689 - mTOR mutations are not associated with shorter PFS and OS in patients treated with mTOR inhibitors
Presenter: Cristina Suarez Rodriguez
Session: Poster Display session 3
Resources:
Abstract
3069 - Efficacy of immune checkpoint inhibitors (ICI) and genomic alterations by body mass index (BMI) in Advanced Renal Cell Carcinoma (RCC)
Presenter: Aly-Khan Lalani
Session: Poster Display session 3
Resources:
Abstract
5089 - Finding the Right Biomarker for Renal Cell Carcinoma (RCC): Nivolumab treatment induces the expression of specific peripheral lymphocyte microRNAs in patients with durable and complete response.
Presenter: Lorena Incorvaia
Session: Poster Display session 3
Resources:
Abstract
2594 - Algorithms derived from quantitative pathology can be a gatekeeper in patient selection for clinical trials in localised clear cell renal cell carcinoma (ccRCC)
Presenter: In Hwa Um
Session: Poster Display session 3
Resources:
Abstract
2566 - High baseline blood volume is an independent favorable prognostic factor for overall and progression-free survival in patients with metastatic renal cell carcinoma
Presenter: Aska Drljevic-nielsen
Session: Poster Display session 3
Resources:
Abstract
2675 - Impact of estimand selection on adjuvant treatment outcomes in renal cell carcinoma (RCC)
Presenter: Daniel George
Session: Poster Display session 3
Resources:
Abstract
1541 - TERT gene fusions characterize a subset of metastatic Leydig cell tumors
Presenter: Bozo Kruslin
Session: Poster Display session 3
Resources:
Abstract